Motiva Implants ® (Establishment Labs Holdings Inc., NY, USA) contains a RFID micro transponder RFID (RT) (RT = registered trademark) known as Q Inside Safety Technology which provides an added safety feature embedded in the shell of the Motiva breast implant [1] [2]. Because this RFID micro transponder has Ferric components, a concern over breast MRI imaging susceptibility artifact has arisen. Among breast images, a single high risk breast cancer patient was imaged at our institution (January 2018). All breast imaging modalities were used to determine if this high risk patient had a recurrence of her cancer or any new breast cancer. The MRI showed a susceptibility artifact on the posterior margin of the implant but breast ultrasound showed no abnormalities in the area of the susceptibility artifact. By using high risk screening including Mammography, Tomosynthesis, Breast Ultrasound and Breast MRI, an adequate survey of the high risk patient was completed [3]. Our high risk clinic examined the patient and the imaging results and came to the following conclusion: This patient showed no evidence of recurrent cancer and no new masses were identified. The conclusion was BIRADS 2 benign: normal findings post-mastectomy and implants. Recommendation was for routine high risk screening at yearly interval.
We present a 55-year-old female, G3P2 with first birth at age 31 and menarche at 11 who has a history of breast cancer. The patient underwent bilateral mastectomy in 2010 for left breast cancer with breast implant placement and chemotherapy. In 2017, the patient has breast surgery revision with new silicone implants. The new silicone breast implants contain a radio frequency identification device micro-transponder (RFID-M), known as the Q Inside Safety TechnologyTM, as an added safety feature embedded in the shell of its breast implant. This RFID-M device allows for the rapid unique identification of implants through a three-point authentication system that contains important information about the implants manufacturing date, serial number, volume, and size [
The purpose for reporting this case is to present a patient with silicone breast implants that contains an RFID device and how it impacts imaging surveillance. The RFID causes a susceptibility artifact that is cuboidal in shape and along the posterior wall of the breast implant near the region of the chest wall. This may reduce the accuracy of identifying recurrent cancer in this region on MRI. However, the addition of breast ultrasound to the breast MRI may help visualize this region and improve visualization of cancer recurrence.
Some patients with breast implants are those with reconstruction for treatment of breast cancer. The risk of cancer recurrence is uniform along the chest wall and therefore this is directly impacted by the size of the susceptibility artifact on MRI.
Currently, the FDA does not specify a method to directly mark a device for identification [
robust breast device registries (Cooter et al. Breast. 2014). They concluded that breast implants are high risk devices that are distributed internationally. Failure to maintain an adequate registry of such devices can have a global impact with potential risk of becoming an international crisis. The Poly Implants Prothèse (PIP) case has had a large global impact at an international level which impacted nearly 400,000 patients raising concerns on the regulatory and quality control procedures that failed to safeguard many women from health risks associated with PIP breast implants (Berry et al. A product recall study) [
We believe that the value of the RFID device on the breast implant outweighs the detrimental effect of the susceptibility artifact on MRI. Furthermore, we feel that the use of breast ultrasound in addition to the breast MRI will improve a radiologist accuracy for assessing the posterior region of the implant and chest wall in patients undergoing surveillance.
Using all breast imaging modalities: digital mammography, tomosynthesis, dedicated breast ultrasound, and contrast subtraction MRI were all completed in this case for this patient with high risk screening [
Dr. Michael Nelson and Dr. Sina Meisamy are paid consultants from JAMM Technologies, Inca subsidiary of Establishment Labs; however, neither Dr. Nelson nor Dr. Meisamy has any conflicts of personal interests in the material and conclusions of this paper. Neither physician has any stock or ownership in ELabs or JAMM Technologies, Inc.
The authors declare no conflicts of interest regarding the publication of this paper.
Nelson, M.T. and Meisamy, S. (2019) High Risk Breast Cancer Patient with Silicone Breast Implant and Q Inside SafetyTM Micro Transponder. Open Journal of Medical Imaging, 9, 52-57. https://doi.org/10.4236/ojmi.2019.94005